Document Detail


Calcium antagonists and sympathetic activity in congestive heart failure.
MedLine Citation:
PMID:  9856378     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To review the sympathetic abnormalities occurring in heart failure, their pathophysiological importance and clinical relevance, and the effects of drug treatment, with particular reference to calcium antagonists.
SYMPATHETIC ACTIVATION IN HEART FAILURE: Indirect and direct approaches to study sympathetic function in humans have documented conclusively that sympathetic activation represents a hallmark of cardiac failure syndrome. Evidence indicates that sympathetic overactivity is associated with, and probably caused by, a baroreflex impairment and that it has adverse effects on patients' prognosis and survival.
GOALS OF DRUG TREATMENT IN CONGESTIVE HEART FAILURE: In the past, drug treatment in heart failure was aimed at improving patients' survival by ameliorating cardiac hemodynamics. It is now established that a major goal of therapeutic intervention is also to reduce sympathetic activation characterizing heart failure.
CALCIUM ANTAGONISTS IN HEART FAILURE: Studies with short-acting calcium antagonists show that they enhance sympathetic activation and that this has an adverse effect on patients' survival. In contrast, third generation calcium antagonists such as amlodipine, which have a slow onset and long duration of action, do not adversely affect sympathetic function and reflex cardiovascular control. Indeed, evidence suggests calcium antagonists with this profile may exert favorable clinical effects.
Authors:
G Grassi; G Bertinieri; C Turri; R Dell'Oro; G Mancia
Related Documents :
19010178 - Study of the adrenergic heart innervation with iodine 123-metaiodobenzylguanidine in he...
12114848 - A phenomenon of heart-rate turbulence, its evaluation, and prognostic value.
8545728 - Acute pseudo-obstruction of the colon (ogilvie's syndrome) following caesarean section ...
9428618 - Myocardial determinants in regulation of the heart rate.
10577408 - New-generation anticoagulants: the low molecular weight heparins.
21427508 - Serum levels of thiobarbituric acid-reactive substances are associated with risk of cor...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Journal of hypertension. Supplement : official journal of the International Society of Hypertension     Volume:  16     ISSN:  0952-1178     ISO Abbreviation:  J Hypertens Suppl     Publication Date:  1998 Oct 
Date Detail:
Created Date:  1999-02-22     Completed Date:  1999-02-22     Revised Date:  2013-07-15    
Medline Journal Info:
Nlm Unique ID:  8501422     Medline TA:  J Hypertens Suppl     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  S9-14     Citation Subset:  IM    
Affiliation:
Cattedra di Medicina Interna I, Ospedale S. Gerado dei Tintori, Monza, Università di Milano, Centro di Fisiologia Clinica e Ipertensione, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Baroreflex / drug effects
Blood Pressure / drug effects
Calcium Channel Blockers / therapeutic use*
Heart Failure / drug therapy*,  physiopathology
Heart Ventricles / drug effects,  innervation*,  physiopathology
Humans
Prognosis
Stroke Volume / drug effects
Sympathetic Nervous System / drug effects,  physiopathology*
Chemical
Reg. No./Substance:
0/Calcium Channel Blockers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cardiovascular risks of hypertension: lessons from observational studies.
Next Document:  Two-year follow-up study to evaluate the reduction of left ventricular mass and diastolic function i...